Results 31 to 40 of about 700,500 (193)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events? [PDF]

IJID Reg, 2023
Background: There has been significant international interest in heterologous prime-boost COVID-19 vaccination. However, it is linked with different intensity and frequency of adverse events.
Haji A, Alkattan A, Mahmoud N, Elkagam E, Hassanein M, Alfaifi A, Al-Tawfiq JA, Alabdulkareem K, Jokhdar H, Radwan N.   +9 more
europepmc   +2 more sources

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. [PDF]

Lancet Infect Dis, 2021
Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, Tinnefeld K, Mijocevic H, Schober K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U, DZIF-VACCELERATE-CoVaKo study team.   +19 more
europepmc   +5 more sources

Heterologous Prime-Boost Vaccination With VLA2001 and an ORFV-Based Vector Enhances Spike- and Nucleocapsid-Specific Immunity in Mice [PDF]

Frontiers in Immunology
Alex Dulovic, Melanie Müller, Alena Reguzova   +2 more
exaly   +2 more sources

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. [PDF]

Vaccine, 2022
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven to be a successful strategy for prevent severe infections. CoronaVac and BNT162b2 are the most used vaccines worldwide, but their use in heterologous vaccination schedules is still subjected to evaluation.Fifty healthy individuals who received heterologous prime-
Rammauro F, Carrión F, Olivero-Deibe N, Fló M, Ferreira A, Pritsch O, Bianchi S.   +6 more
europepmc   +4 more sources

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia? [PDF]

Front Public Health, 2022
Gelanew T, Wassie L, Mulu A, Wondwossen L, Abebe M, Mihret A, Abdissa A.   +6 more
europepmc   +4 more sources

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. [PDF]

Biomed Pharmacother, 2022
The objective of the present work was to assess the reactogenicity and immunogenicity of heterologous COVID-19 vaccination regimens in clinical trials and observational studies.PubMed, Cochrane Library, Embase, MedRxiv, BioRxiv databases were searched in September 29, 2021. The PRISMA instruction for systemic review was followed.
Nguyen TT, Quach THT, Tran TM, Phuoc HN, Nguyen HT, Vo TK, Vo GV.   +6 more
europepmc   +3 more sources

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

The Lancet Regional Health. Europe, 2021
Summary: Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
Peter Nordström, Marcel Ballin, Anna Nordström   +2 more
doaj   +1 more source

Heterologous prime-boost immunization with CoronaVac and Convidecia [PDF]

, 2021
ABSTRACT Background The safety and immunogenicity of heterologous prime-boost COVID-19 vaccine regimens with one shot of a recombinant adenovirus type-5-vectored COVID-19 vaccine Convidecia has not been reported.
Jingxin Li, Lihua Hou, Xiling Guo, Pengfei Jin, Shipo Wu, Jiahong Zhu, Hongxing Pan, Xue Wang, Zhizhou Song, Jingxuan Wan, Lunbiao Cui, Junqiang Li, Xuewen Wang, Lairun Jin, Jingxian Liu, Fengjuan Shi, Xiaoyu Xu, Yin Chen, Tao Zhu, Wei Chen, Fengcai Zhu   +20 more
openaire   +1 more source

Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing. [PDF]

ACS Nano
Abstract Protein nanoparticles are effective platforms for antigen presentation and targeting effector immune cells in vaccine development. Encapsulins are a class of protein-based microbial nanocompartments that self-assemble into icosahedral structures with external diameters ranging from 24 to 42 nm.
Bhattacharya S, Jenkins MC, Keshavarz-Joud P, Bourque AR, White K, Alvarez Barkane AM, Bryksin AV, Hernandez C, Kopylov M, Finn MG.   +9 more
europepmc   +4 more sources

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies

Frontiers in Immunology, 2022
mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody ...
Anne-Cathrine S. Vogt, Anne-Cathrine S. Vogt, Lukas Jörg, Lukas Jörg, Byron Martina, Byron Martina, Pascal S. Krenger, Pascal S. Krenger, Xinyue Chang, Xinyue Chang, Andris Zeltins, Monique Vogel, Monique Vogel, Mona O. Mohsen, Mona O. Mohsen, Martin F. Bachmann, Martin F. Bachmann, Martin F. Bachmann   +17 more
doaj   +1 more source